CASI Pharmaceuticals (CASIF) Other Accumulated Expenses (2021 - 2025)

CASI Pharmaceuticals has reported Other Accumulated Expenses for 5 years, with the latest figure at $3.7 million in Q4 2025.

• For the quarter ending Q4 2025, Other Accumulated Expenses rose 10.32% year-over-year to $3.7 million; the trailing twelve-month figure through Dec 2025 stood at $3.7 million (up 10.32% YoY), and the FY2025 full-year result was $3.7 million, up 10.32% from the prior year.
• Other Accumulated Expenses for Q4 2025 stood at $3.7 million, up from $3.3 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $3.7 million in Q4 2025, with the low at $1.1 million in Q4 2023.
• Historically, Other Accumulated Expenses has averaged $2.9 million across 5 years, with a median of $3.3 million in 2024.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses slumped 61.59% — and 2024, when it soared 198.12%.
• CASI Pharmaceuticals' Other Accumulated Expenses stood at $3.3 million in 2021, then dropped by 12.74% to $2.9 million in 2022, then tumbled by 61.59% to $1.1 million in 2023, then soared by 198.12% to $3.3 million in 2024, then climbed by 10.32% to $3.7 million in 2025.
• The last three Other Accumulated Expenses figures came in at $3.7 million (Q4 2025), $3.3 million (Q4 2024), and $1.1 million (Q4 2023), per Business Quant data.